Brigham and Women's Hospital
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Brigham and Women's Hospital sits in the top decile of US sponsors by registered trial count (#35 of 15,742 sponsors by registered trial count).
Brigham and Women's Hospital: 937 sponsored US clinical trials, 145 recruiting.
Brigham and Women's Hospital sponsors 937 registered US clinical trials on ClinicalTrials.gov, 145 of them currently recruiting, and 608 completed. 124 of these trials are in Phase 3-4 (later-stage) and 197 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Type 2 Diabetes, with 13 trials.
Top-decile sponsor footprint
Brigham and Women's Hospital ranks in the top decile of sponsors by registered trial count (#35 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
608 of 677 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (89.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
937 total, page 16 of 19
The Efficacy of Diclofenac Gel for Breakthrough Pain and the Neuropathic Components of Pain in Knee Osteoarthritis
NCT01383954
Collar Immobilization Following a Posterior Cervical Laminectomy and Fusion
NCT01383876
Prediction of Findings From the Ongoing CAROLINA Trial Using Healthcare Database Analyses
NCT03648424
Optimizing Protein Intake in Older Americans With Mobility Limitations
NCT01275365
Sorbent Therapy of the Cutaneous Porphyrias
NCT01422915
Use and Effectiveness of a Model Integrative Care Clinic in an Academic Hospital: Study 1-Survey
NCT01353560
A Risk Based Approach to Improving Chronic Kidney Disease Management
NCT01203813
Oral OKT3 for the Treatment of Active Ulcerative Colitis
NCT01287195
Oxytocin And Uterotonic Agent Use For Cesarean Delivery
NCT01549223
Prediction of Outcomes Following Total Knee Replacement
NCT01370421
Blacks and Exacerbations on Long Acting Beta Agonists (LABA) vs. Tiotropium (BELT)
NCT01290874
Multi-Center Medication Reconciliation Quality Improvement Study
NCT01337063
Demonstration of Near Zero Antibiotic Prescribing for Acute Bronchitis
NCT01240174
Sleep Apnea Intervention for Cardiovascular Disease Reduction
NCT01261390
Study of Vitamin D and Uric Acid Lowering on Kidney and Blood Vessel Function
NCT01320722
Integrated Dual Exercise and Lexiscan Positron Emission Tomography: IDEALPET
NCT01109992
Hypoglycemia and the Mineralocorticoid Receptor
NCT01394627
Milnacipran in the Treatment of Widespread, Non-Joint Pain in Rheumatoid Arthritis
NCT01207453
Development of a Sign-Out Tool to Improve Handoffs in Care
NCT01398761
Barbed Suture vs Smooth Suture for Vaginal Cuff Closure
NCT01262573
Quantification of Human Adipogenesis
NCT01257997
Effects of Intravenous Lidocaine on Endometriosis Pain
NCT01968694
Effects of cKit Inhibition by Imatinib in Patients With Severe Refractory Asthma (KIA)
NCT01097694
Integrating Patient Generated Family Health History From Varied Electronic Health Record (EHR) Entry Portals
NCT00977847
Light Sensitization Study
NCT01327040
An Automatic Notification System for Test Results Finalized After Discharge
NCT01153451
Clinical Trial of a Silver Eluting Dressing System
NCT01229358
Omega-3 Fatty Acids for Prevention of Post-Operative Atrial Fibrillation
NCT00970489
Dietary Fat and High-Density Lipoprotein (HDL) Metabolism-Effect of Carbohydrate and Fat Intake
NCT01399632
Vitamin D and Fish Oil for Autoimmune Disease, Inflammation and Knee Pain
NCT01351805
VITAL-DEP: Depression Endpoint Prevention in the VITamin D and OmegA-3 TriaL
NCT01696435
Positive Airway Pressure for the Treatment of Asthma
NCT01154699
Novel Pathways to Manage Inflammation and Atherosclerosis in Dialysis Patients: Role of Nicotinic Acid
NCT01159054
Hydroxychloroquine to Improve Insulin Sensitivity in Rheumatoid Arthritis
NCT01132118
Assessment of Renin Inhibition on Insulin Sensitivity, Diastolic Function and Aortic Compliance
NCT01252238
Improving Glycemic Control on GMS: A Quality Improvement Study
NCT00271700
Altered Brain GABA and Glutamate in Restless Legs Syndrome
NCT01109537
Effect of Short Term Aliskiren Treatment in Kidney Transplant Patients
NCT01437943
Effect of Eplerenone on Postprandial Inflammatory Response in Healthy Adults
NCT01786551
Vitamin D Supplementation Reduces Renin-Angiotensin System Activity in Obesity
NCT01068418
Heart Biomarker Evaluation in Apnea Treatment
NCT01086800
Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IV
NCT01434667
Effect of Estradiol+Drospirenone Versus Estradiol+MPA on Endothelial Function
NCT01109979
Human Circadian Sensitivity to Very Short Light Pulses
NCT01330992
Diabetes Prevention in Women With a Recent History of Gestational Diabetes Mellitus (GDM)
NCT01158131
Face Transplantation for Treatment of Severe Facial Deformity
NCT01281267
A Brief Intervention to Improve Cost-effective Resource Use Among Medicine Housestaff
NCT01303263
Does Emotional Support Decrease In Vitro Fertilization Stress?
NCT01406028
Melatonin Treatment for Induced Transient Insomnia
NCT00950885
Randomized Trial: Maternal Vitamin D Supplementation to Prevent Childhood Asthma (VDAART)
NCT00920621
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 90 |
| Phase 2 | 107 |
| Phase 3 | 47 |
| Phase 4 | 77 |
Therapeutic Areas
What is open in the Brigham and Women's Hospital pipeline
145 recruiting of 937 indexed (15% open); 608 completed (65%).
Phase mix: 124 late (III/IV) vs 197 early (I/II) (early-phase heavy).
Top condition: Type 2 Diabetes (13 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Brigham and Women's Hospital: open-pipeline peers nationwide
Peers matched on 937 registered trials and 15% open enrollment, not the therapeutic-area sidebar.
Brigham and Women's Hospital sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 937 trials (± recruiting share)
- Columbia University · 958 trials · 18% recruiting
- Hoffmann-La Roche · 909 trials · 8% recruiting
- University of Minnesota · 966 trials · 19% recruiting
- University of California, Los Angeles · 897 trials · 18% recruiting
Sponsors near 15% open enrollment (± trial volume)
- Incyte Corporation · 15% recruiting · 239 trials
- Northwestern University · 15% recruiting · 1,209 trials
- Nationwide Children's Hospital · 15% recruiting · 188 trials
- University of Michigan Rogel Cancer Center · 15% recruiting · 292 trials
Related
What to do with this Brigham and Women's Hospital page
937 registered trials is a research-attention snapshot, not an endorsement of Brigham and Women's Hospital or any single study.
- 145 of Brigham and Women's Hospital's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Type 2 Diabetes is the condition Brigham and Women's Hospital studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Type 2 Diabetes trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Brigham and Women's Hospital pipeline card: 937 registered trials from official public datasets.Report a data error.